MRI引导高剂量率近距离放疗前列腺癌消融剂量局灶单药治疗的剂量学可行性
本研究评估MRI引导高剂量率近距离放疗(HDR-BT)前列腺癌(PCa)局灶单药治疗中剂量递增的剂量学可行性。发现队列(20例患者,32个GTV)中,47%的GTV能达到PTV D95%≥16.5Gy,50%的计划可行单次剂量方案;验证队列(10例患者,10个GTV,两次独立植入)中计划100%满足可接受标准,43-100%满足理想标准,35%的植入可行单次剂量方案。结论认为该局灶消融剂量递增方案可行,需前瞻性研究确定临床结局。
要点
- 发现队列中47%的GTV达到PTV D95%≥16.5Gy,50%计划可行单次剂量方案。
- 验证队列计划100%满足可接受标准,43-100%满足理想标准。
- 35%的植入可行单次剂量方案,未放宽OAR约束或增加正常前列腺剂量。
核心结论
- 所提出的方案对前列腺癌局灶消融剂量递增放疗是可行的。
- 需要前瞻性研究来确定临床结局。
研究设计与样本
- 发现队列20例患者共32个GTV,验证队列10例患者共10个GTV(每个GTV两次独立植入)。
- GTV由mpMRI定义并形变配准至插管后计划MRI,PTV包括GTV加头脚方向9mm和其他方向5mm。
- 计划目标为分次剂量≥16.5Gy(两分次方案),或达到等效单次剂量计划(24Gy)时停止,同时遵守预定义的OAR约束。
主要发现
- 发现队列中,单个计划无法达到PTV D95%≥16.5Gy的情况占3%。
- 发现队列中,15个GTV(47%)达到PTV D95%≥16.5Gy,范围为16.5-23.8Gy。
- 发现队列中,16个计划(50%)可行单次剂量方案。
- 验证队列中,计划满足可接受标准和理想标准的比例分别为100%和43-100%。
- 验证队列中,7次植入(35%)可行单次剂量方案,未放宽OAR约束或增加mpMRI正常前列腺的剂量(D100%和D35%,p>0.05)。
关键数值与推荐
- PTV D95%目标≥16.5Gy/分次(两分次方案),等效单次剂量计划为24Gy。
- PTV包括GTV加头脚方向9mm和其他方向5mm。
- 验证队列计划满足可接受标准100%,理想标准43-100%。
临床怎么用
- 对于前列腺癌局灶单药治疗,可考虑MRI引导HDR-BT消融剂量递增方案。
- 部分患者(35-50%)可迁移至单次剂量方案而不放宽OAR约束。
局限性
- 研究为剂量学可行性研究,未报告临床结局。
- 样本量较小(发现队列20例,验证队列10例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the dosimetric feasibility of dose-escalated MRI-guided high-dose-rate brachytherapy (HDR-BT) focal monotherapy for prostate cancer (PCa). METHODS: In all patients, GTV was defined with mpMRI, and deformably registered onto post-catheter insertion planning MRI. PTV included the GTV plus 9mm craniocaudal and 5mm in every other direction. In discovery-cohort, plans were obtained for each PTV independently aiming to deliver ⩾16.5Gy/fraction (two fraction schedule) while respecting predefined organs-at-risk (OAR) constraints or halted when achieved equivalent single-dose plan (24Gy). Dosimetric results of original and focal HDR-BT plans were evaluated to develop a planning protocol for the validation-cohort. RESULTS: In discovery-cohort (20-patients, 32-GTVs): PTV D95% ⩾16.5Gy could not be reached in a single plan (3%) and was accomplished (range 16.5-23.8Gy) in 15 GTVs (47%). Single-dose schedule was feasible in 16 (50%) plans. In the validation-cohort (10-patients, 10-GTVs, two separate implants each): plans met acceptable and ideal criteria in 100% and 43-100% respectively. Migration to single-dose treatment schedule was feasible in 7 implants (35%), without relaxing OAR's constraints or increasing the dose (D100% and D35%) to mpMRI-normal prostate (p>0.05). CONCLUSION: Focal ablative dose-escalated radiation is feasible with the proposed protocol. Prospective studies are warranted to determine the clinical outcomes.
引用
- Hosni A, Carlone M, Rink A, et al. Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. Radiother Oncol. 2016. PMID: 27916416. doi:10.1016/j.radonc.2016.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。